Camp4 Therapeutics Corp

UCD program

•Preclinical data

o In Otc-deficient mice, treatment with CMP-CPS-001 resulted in dose-dependent reductions in ammonia levels, which persisted for approximately 4 weeks

Increases in mRNA levels of additional enzymes of the urea cycle were observed, suggesting increased metabolic activity

o In mice with humanized livers, administration of CMP-CPS-001 following an ammonia challenge resulted in increased ureagenesis and decreased ammonia levels

o Administration of CMP-CPS-001 in NHPs resulted in up to 40% increase in ureagenesis, supporting the MOA to convert ammonia to urea

•Phase 1 clinical data

o 48 healthy adult participants were enrolled across four SAD cohorts and randomized 3:1 to a single subcutaneous dose of CMP-CPS-001, with 36 participants randomized to CMP-CPS-001

o CMP-CPS-001 was well tolerated, with no evidence of a maximum tolerated dose and no safety trends of concern

o All treatment-emergent adverse events (TEAEs) were Grade 1 (mild) or Grade 2 (moderate) with no serious or severe adverse events (AEs) or TEAEs and no participants discontinued study drug due to a TEAE

Most common TEAEs were headache (n=6) followed by nausea (n=4)

o Pharmacokinetics

Dose-dependent increase in exposure (Cmax and AUC) with clear separation between dose levels

Greater than dose-proportional increase in exposure (Cmax and AUC0-24)

•Study Update

o Dosing complete in MAD Cohort 1 through Cohort 3

o Anticipate expansion into OTC heterozygotes to assess safety and CMP-CPS-001 effect on ureagenesis in patients with evidence of reduced urea cycle function

The presentations can be accessed on the CAMP4 website athttps://investors.camp4tx.com/news-events/presentations after the presentations.